BioCentury
ARTICLE | Tools & Techniques

J&J intercepts Nextera

How Nextera technology could enable J&J to intercept RA before it starts

October 5, 2015 7:00 AM UTC

Johnson & Johnson's option deal with Nextera A/S could add another tool to the pharma's growing arsenal of T cell-based technologies for intercepting immunological diseases before they start.

On Sept. 21, Nextera granted J&J's Janssen Biotech Inc. unit an option to exclusively license the biotech's Phagemer technology for rheumatoid arthritis. Janssen initially will fund a research program. Additional details of the deal, including what triggers the option, were not disclosed...